Last reviewed · How we verify
NgG high dose investigational vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
NgG high dose investigational vaccine (NgG high dose investigational vaccine) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NgG high dose investigational vaccine TARGET | NgG high dose investigational vaccine | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NgG high dose investigational vaccine CI watch — RSS
- NgG high dose investigational vaccine CI watch — Atom
- NgG high dose investigational vaccine CI watch — JSON
- NgG high dose investigational vaccine alone — RSS
Cite this brief
Drug Landscape (2026). NgG high dose investigational vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/ngg-high-dose-investigational-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab